IDEAYA Biosciences (IDYA) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 98.6% versus a gain of 34.4%. Over five years, TVTX leads with a +112.4% price change compared with +55.9% for IDYA. Travere Therapeutics is the larger company by market cap ($4.91 billion vs $3.50 billion), about 1.4 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +110.5%).
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | TVTX |
|---|---|---|
| Share price | $36.26 | $52.07 |
| Market cap | $3.50B | $4.91B |
| 1-day change | +0.55% | +0.05% |
| YTD return | +4.31% | +36.19% |
| 1-year return | +34.35% | +98.63% |
| 5-year return | +55.90% | +112.41% |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-1.94 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $490.73M |
| Revenue growth (YoY) | +3024.43% | +110.45% |
| Net income (latest FY) | $-113.70M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | -72.84% | -12.80% |
| Net margin | -51.99% | -5.21% |
| 52-week high | $42.68 | $68.73 |
| 52-week low | $26.05 | $22.59 |
| Distance from 52-week high | -15.04% | -24.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +45.48% | +44.45% |
| Average volume | 779.15K | 1.59M |
| Shares outstanding | 96.49M | 94.26M |
| Employees | 145 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed IDYA by 64.3 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +110.45%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
IDYA vs TVTX FAQ
Which is bigger, IDEAYA Biosciences or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.91B compared with $3.50B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +34.35% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.